Cigna (CI) AI Stock Analysis

• Market Cap: $77.04B
• Dividend Yield: 2.03%
• Average Volume (3M): 1.48M
• Price to Earnings (P/E): 15.8
• Beta (1Y): 0.27
• Revenue Growth: 20.93%
• EPS Growth: 43.98%
• Country: US
• Employees: 71,295
• Sector: Healthcare
• Sector Strength: 45
• Industry: Insurance - Brokers
• EPS (TTM): 7.20
• Shares Outstanding: 266,928,070
• 10 Day Avg. Volume: 1,442,061
• 30 Day Avg. Volume: 1,481,338
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.55
• Enterprise Value/Revenue: 0.46
• Enterprise Value/Gross Profit: 4.34
• Enterprise Value/Ebitda: 9.70
• 1Y Price Target: $367.42
• Price Target Upside: 26.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 19

• Rating: 73 Outperform
• Price Target: $331.00 ▲(13.58% Upside)

Cigna's overall stock score is driven by strong financial performance and positive earnings call sentiment, highlighting strategic growth initiatives and robust guidance. While technical analysis and valuation present a more neutral outlook, the company's focus on innovation and partnerships supports a positive long-term trajectory.

Positive Factors

Revenue Growth

Cigna's strong revenue growth underscores its expanding market presence and effective service offerings, supporting long-term financial health.

Strategic Investments

The investment in Shields Health Solutions enhances Evernorth's capabilities in specialty pharmacy management, strengthening Cigna's competitive position.

Earnings Guidance

Cigna's reaffirmed earnings guidance reflects management's confidence in sustaining growth and navigating industry challenges effectively.

Negative Factors

Cash Flow Challenges

Significant decline in free cash flow growth indicates potential liquidity constraints, which could impact Cigna's ability to invest in growth initiatives.

Elevated Medical Costs

Rising medical costs could pressure margins and profitability, challenging Cigna's ability to maintain competitive pricing and service quality.

Stop-Loss Margin Challenges

Current margin challenges in the stop-loss business may affect profitability, requiring strategic adjustments to enhance long-term financial performance.

Cigna Business Overview & Revenue Model

Company Description

Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care delivery and management, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans to on and off the public exchanges; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

How the Company Makes Money

Cigna generates revenue primarily through premiums collected from its health insurance policies, which cover a variety of services including medical, dental, and pharmacy care. The company also earns revenue from providing managed care services to employers and government programs. Key revenue streams include individual and group health insurance premiums, administrative services for self-funded employer plans, and sales of ancillary products like dental and vision insurance. Additionally, Cigna has strategic partnerships and collaborations with healthcare providers, which enable them to optimize costs and improve care delivery. The company also benefits from the increasing demand for healthcare services and the expansion of health insurance coverage, particularly in the context of regulatory changes and market dynamics.

Cigna Financial Statement Overview

Summary

Cigna demonstrates strong revenue growth and profitability improvements, particularly in net profit margin. The balance sheet is stable with moderate leverage, but cash flow challenges, particularly in free cash flow growth, present potential risks. Continued focus on operational efficiency and cash flow management will be crucial for sustaining financial health.

Income Statement

Cigna's income statement shows a solid performance with a consistent revenue growth rate of 2.63% in the TTM period. The gross profit margin is strong at 10.62% annually, and the net profit margin has improved to 1.92% in the TTM. However, the EBIT and EBITDA margins are relatively modest, indicating room for operational efficiency improvements.

Balance Sheet

The balance sheet reflects a stable financial position with a manageable debt-to-equity ratio of 0.77 in the TTM, indicating moderate leverage. The return on equity is healthy at 12.27%, showcasing effective use of equity capital. However, the equity ratio is not explicitly provided, which limits a full assessment of asset financing.

Cash Flow

Cigna's cash flow statement indicates challenges with a significant decline in free cash flow growth by 34.38% in the TTM. The operating cash flow to net income ratio is low at 0.09, suggesting potential liquidity constraints. However, the free cash flow to net income ratio remains robust at 0.75, indicating efficient cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	262.07B	247.12B	195.26B	180.52B	174.07B	160.40B
Gross Profit	27.56B	25.96B	25.18B	23.50B	22.95B	24.21B
EBITDA	12.33B	11.45B	10.85B	10.44B	9.96B	10.37B
Net Income	5.02B	3.43B	5.16B	6.70B	5.37B	8.46B
Balance Sheet
Total Assets	151.65B	155.88B	152.76B	143.88B	154.89B	155.45B
Cash, Cash Equivalents and Short-Term Investments	5.14B	8.21B	8.75B	6.83B	6.00B	11.51B
Total Debt	30.77B	31.97B	30.93B	31.55B	34.27B	33.56B
Total Liabilities	111.22B	114.64B	106.41B	98.98B	107.70B	105.06B
Stockholders Equity	40.21B	41.03B	46.22B	44.87B	47.11B	50.32B
Cash Flow
Free Cash Flow	3.94B	8.96B	10.24B	7.36B	6.04B	9.26B
Operating Cash Flow	5.29B	10.36B	11.81B	8.66B	7.19B	10.35B
Investing Cash Flow	-567.00M	-2.10B	-5.17B	3.10B	-3.61B	2.98B
Financing Cash Flow	-7.82B	-7.65B	-4.29B	-11.24B	-8.21B	-8.53B

Cigna Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 291.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CI, the sentiment is Negative. The current price of 291.43 is below the 20-day moving average (MA) of 297.95, below the 50-day MA of 292.26, and below the 200-day MA of 302.42, indicating a bearish trend. The MACD of -1.14 indicates Positive momentum. The RSI at 44.01 is Neutral, neither overbought nor oversold. The STOCH value of 14.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CI.

Cigna Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVS	77 Outperform	96.87B	21.34	5.86%	3.48%	6.27%	-36.28%
CI	73 Outperform	$77.04B	15.76	12.31%	2.03%	20.93%	43.98%
UNH	72 Outperform	318.63B	15.06	22.48%	2.45%	9.98%	52.31%
ELV	71 Outperform	73.49B	13.78	12.26%	2.07%	10.21%	-17.79%
CNC	70 Outperform	17.02B	8.57	7.49%	―	12.96%	-23.25%
HUM	70 Outperform	31.51B	19.83	8.64%	1.35%	9.88%	-7.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Cigna Corporate Events

Cigna Issues $4.5 Billion in Senior Notes

On September 4, 2025, Cigna completed a significant financial maneuver by issuing $4.5 billion in senior notes with varying maturity dates and interest rates. The proceeds from this issuance are intended to repay $2 billion in loans used for a strategic investment and support general corporate purposes, potentially impacting the company’s financial flexibility and strategic positioning.

The most recent analyst rating on (CI) stock is a Buy with a $383.00 price target. To see the full list of analyst forecasts on Cigna stock, see the CI Stock Forecast page.

Cigna Reaffirms 2025 Earnings Projection Amid Industry Challenges

The Cigna Group, a prominent player in the healthcare industry, has reaffirmed its projected full-year 2025 consolidated adjusted income from operations, expecting at least $29.60 per share. This announcement, initially discussed in July 2025, underscores Cigna’s confidence in its financial performance and strategic positioning despite the inherent uncertainties and risks in the evolving healthcare sector.

The most recent analyst rating on (CI) stock is a Buy with a $335.00 price target. To see the full list of analyst forecasts on Cigna stock, see the CI Stock Forecast page.